Recent data from Pfizer, Boehringer Ingelheim, and others show new obesity drugs struggling to significantly outperform market leaders. This suggests the industry may be reaching a point of diminishing returns on efficacy, making it difficult for new entrants to compete on that metric alone and raising the bar for future innovation.

The standard of care for melanoma is improving so quickly that control arms in recent clinical trials are significantly outperforming historical data. This 'rising tide' effect makes it increasingly difficult for new drugs to show a statistically significant benefit, creating high unpredictability for developers.

Novartis's cardio drug failure in a secondary prevention trial highlights a critical development challenge: even for genetically-validated targets, intervening late in a chronic disease's progression may be ineffective. The damage may already be too extensive, suggesting earlier treatment is needed to show a benefit.

Novartis's Lp(a) drug may have failed not because the target is wrong, but because patients were already so well-treated with existing drugs like statins. This highlights a growing challenge: new therapies must demonstrate significant added value over an increasingly effective standard of care.

Two major cardiovascular trials targeting novel biomarkers (LPA and hs-CRP) failed to improve outcomes despite successfully lowering the biomarkers. This has dampened enthusiasm for novel targets and shifted R&D and investor focus back to established, "unsexy" pathways like PCSK9, GLP-1, and SGLT2, which are now viewed as less risky.

Successful drug launches require nailing three fundamentals. Common failures include: misjudging the patient population (epidemiology), failing to secure reimbursement and patient access, and lacking clear differentiation against the established "gold standard" treatment in physicians' minds.

The primary hurdle in drug development is the Phase 2 trial, where the most frequent cause of failure is a simple lack of efficacy. It is not typically due to safety concerns, business case changes, or target engagement issues, but rather that the drug produces no therapeutic effect upon administration.

Despite major scientific advances, the key metrics of drug R&D—a ~13-year timeline, 90-95% clinical failure rate, and billion-dollar costs—have remained unchanged for two decades. This profound lack of productivity improvement creates the urgent need for a systematic, AI-driven overhaul.

Following the costly trial failures of Novartis and Novo Nordisk, investors are expected to become highly risk-averse toward cardiovascular drug development. This will create a challenging funding environment for startups in the space as capital shifts to less risky therapeutic areas.